AlphaFold-based peptide structure prediction: Opportunities, limitations, and future directions.

Abstract

Accurate prediction of peptide structures and peptide-receptor complexes is essential for rational peptide drug development. However, the inherent conformational flexibility of short and disordered peptides presents a fundamental challenge. The AlphaFold model series, which has progressed from AlphaFold2 through AlphaFold-Multimer to AlphaFold3, has substantially advanced computational peptide structure prediction through innovations in geometric reasoning (invariant point attention) and interface-focused confidence metrics (ipTM score), achieving high accuracy for both monomeric peptide structures and multi-chain complexes. However, these models output static conformations, whereas many bioactive peptides adopt their functional conformations only upon binding-often corresponding to low-probability states that static predictions may overlook, leading to failures in virtual screening. This review synthesizes recent advances in the AlphaFold series for peptide studies and applications, discusses their current strengths in structure prediction and receptor-binding analysis, and examines the limitations in capturing conformational dynamics, transient interactions, and chemical modifications. Recent studies have suggested that integrated computational strategies that combine AlphaFold predictions with molecular dynamics simulations, free energy calculations, and ensemble sampling to enhance predictive accuracy and better represent the dynamic nature of peptide-drug interactions. These complementary approaches position AlphaFold as a central computational platform in structure-guided peptide drug design, enabling more efficient lead identification and optimization while bridging the gap between static computational predictions and the complex biophysical reality of peptide therapeutics.